This was later confirmed by Hideshima and colleagues later who reported that BTZ promotes non-proteasomal degradation of IκB through activation of IKK and RIP2, leading to improved canonical NF-κB activity in both MM cell lines and primary cells [21]. The gene discussed is CASC3; the disease is Miyoshi myopathy.